Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986299 in advanced solid cancers
NCT03444753Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986299 in solid tumor (advanced stage) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of dose-limiting toxicities up to 28 days, Incidence of adverse events and 3 more. Started Apr 2018; status: terminated.
02
Drugs
BMS-986299
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03444753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444753.